NO20042365L - Kombinasjonsterapi omfattende ZD6474 og et taxan - Google Patents

Kombinasjonsterapi omfattende ZD6474 og et taxan

Info

Publication number
NO20042365L
NO20042365L NO20042365A NO20042365A NO20042365L NO 20042365 L NO20042365 L NO 20042365L NO 20042365 A NO20042365 A NO 20042365A NO 20042365 A NO20042365 A NO 20042365A NO 20042365 L NO20042365 L NO 20042365L
Authority
NO
Norway
Prior art keywords
taxane
combination therapy
therapy
combination
Prior art date
Application number
NO20042365A
Other languages
English (en)
Other versions
NO328048B1 (no
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab Global Ip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab Global Ip filed Critical Astrazeneca Ab Global Ip
Publication of NO20042365L publication Critical patent/NO20042365L/no
Publication of NO328048B1 publication Critical patent/NO328048B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20042365A 2001-11-08 2004-06-07 Farmasoytisk preparat omfattende ZD6474 og et taxan, sett omfattende samme samt anvendelse av samme for fremstilling av medikament for behandling av sykdom NO328048B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0126879.6A GB0126879D0 (en) 2001-11-08 2001-11-08 Combination therapy
PCT/GB2002/005021 WO2003039551A1 (en) 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane

Publications (2)

Publication Number Publication Date
NO20042365L true NO20042365L (no) 2004-06-07
NO328048B1 NO328048B1 (no) 2009-11-16

Family

ID=9925430

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042365A NO328048B1 (no) 2001-11-08 2004-06-07 Farmasoytisk preparat omfattende ZD6474 og et taxan, sett omfattende samme samt anvendelse av samme for fremstilling av medikament for behandling av sykdom

Country Status (23)

Country Link
US (2) US20050043395A1 (no)
EP (1) EP1446124B1 (no)
JP (1) JP4694127B2 (no)
KR (1) KR100959607B1 (no)
CN (1) CN1298328C (no)
AR (1) AR037346A1 (no)
AT (1) ATE335488T1 (no)
AU (1) AU2002337382B2 (no)
BR (1) BR0213906A (no)
CA (1) CA2464758C (no)
CY (1) CY1106259T1 (no)
DE (1) DE60213845T2 (no)
DK (1) DK1446124T3 (no)
ES (1) ES2269769T3 (no)
GB (1) GB0126879D0 (no)
HK (1) HK1068546A1 (no)
IL (2) IL161744A0 (no)
MX (1) MXPA04004355A (no)
NO (1) NO328048B1 (no)
NZ (1) NZ532525A (no)
PT (1) PT1446124E (no)
WO (1) WO2003039551A1 (no)
ZA (1) ZA200403455B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1244647E (pt) 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
EP1274692B1 (en) * 2000-04-07 2006-08-02 AstraZeneca AB Quinazoline compounds
CN101607958A (zh) * 2002-02-01 2009-12-23 阿斯特拉曾尼卡有限公司 喹唑啉化合物
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
WO2004041829A1 (en) 2002-11-04 2004-05-21 Astrazeneca Ab Quinazoline derivatives as src tyrosine kinase inhibitors
WO2004071397A2 (en) * 2003-02-13 2004-08-26 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
CA2531862C (en) * 2003-07-10 2011-10-25 Astrazenca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
CA2571421A1 (en) * 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
BRPI0620140A2 (pt) * 2005-12-22 2011-11-01 Astrazeneca Ab uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e pemetrexed, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou redutor da permeabilidade vascular
MX2008014953A (es) * 2006-05-26 2009-03-05 Bayer Healthcare Llc Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer.
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
NZ589883A (en) 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
WO2010061208A2 (en) * 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
CN106478598B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种凡德他尼水合物晶体及其制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
ATE242635T1 (de) * 1996-04-26 2003-06-15 Magainin Pharma Squalamin in kombination mit anderen antikrebs- mittelen zur behandlung von tumoren
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
CA2362937C (en) * 1999-02-24 2011-03-22 The Uab Research Foundation Taxane derivatives for targeted therapy of cancer
CA2372053C (en) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
PT1244647E (pt) * 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
CA2495487A1 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
WO2004071397A2 (en) * 2003-02-13 2004-08-26 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
CA2531862C (en) * 2003-07-10 2011-10-25 Astrazenca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
BRPI0620140A2 (pt) * 2005-12-22 2011-11-01 Astrazeneca Ab uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e pemetrexed, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou redutor da permeabilidade vascular
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy

Also Published As

Publication number Publication date
IL161744A (en) 2012-01-31
DK1446124T3 (da) 2006-11-13
DE60213845D1 (de) 2006-09-21
DE60213845T2 (de) 2007-03-29
EP1446124B1 (en) 2006-08-09
US20050043395A1 (en) 2005-02-24
GB0126879D0 (en) 2002-01-02
CN1612738A (zh) 2005-05-04
CA2464758A1 (en) 2003-05-15
ZA200403455B (en) 2005-08-29
US20120252827A1 (en) 2012-10-04
CA2464758C (en) 2010-09-28
AR037346A1 (es) 2004-11-03
IL161744A0 (en) 2005-11-20
AU2002337382B2 (en) 2008-06-12
JP4694127B2 (ja) 2011-06-08
EP1446124A1 (en) 2004-08-18
JP2005511597A (ja) 2005-04-28
KR20050043779A (ko) 2005-05-11
HK1068546A1 (en) 2005-04-29
NZ532525A (en) 2006-11-30
CN1298328C (zh) 2007-02-07
NO328048B1 (no) 2009-11-16
MXPA04004355A (es) 2004-08-11
KR100959607B1 (ko) 2010-05-27
PT1446124E (pt) 2006-12-29
WO2003039551A1 (en) 2003-05-15
BR0213906A (pt) 2004-08-31
CY1106259T1 (el) 2011-06-08
ES2269769T3 (es) 2007-04-01
ATE335488T1 (de) 2006-09-15

Similar Documents

Publication Publication Date Title
NO20042365L (no) Kombinasjonsterapi omfattende ZD6474 og et taxan
DK1513873T3 (da) Terapeutiske epitoper og anvendelser deraf
DE60212600D1 (de) Audiocodierung und decodierung
DK1400518T3 (da) Heterocycliske forbindelser og lægemidler
DK1370128T3 (da) Kombineret ballepresse og ballevikler
DK1519770T3 (da) Elektroporesisk indretning og indsprøjtningsapparat
DE60144138D1 (de) Lichtemittierende Vorrichtungen und lichtemittierende Anzeigevorrichtungen
NO20035559D0 (no) Personlig spilleanordning
GB0422040D0 (en) Gaming environment including portable transaction devices
FR2823558B1 (fr) Glaciere portable
GB0203933D0 (en) Portable dummy sterilizer
NO20034022L (no) En kombinasjon omfattende combretastatin og anticancermidler
EP1420348A4 (en) STRING AND PROGRAM
GB2373181B (en) A portable sauna
NO20033709D0 (no) Medisinske preparater omfattende Diklofenak og Ornoprostil
DK1456377T3 (da) Syn3-sammensætninger og fremgangsmåder
AU148766S (en) Portable drill
NO20032821D0 (no) Sea-trosy og beslektede fremgangsmåter
SI1446124T1 (sl) Kombinacijska terapija, ki obsega ZD6474 in taksan
DE60219418D1 (de) Silanylphenole und -naphthole
TW570251U (en) Portable exercise and worship counter device
PL112305U1 (en) Portable game
GB0124464D0 (en) Portable step
GB0100515D0 (en) Music teaching game
ITMS20010006U1 (it) Trattamento criogenico antitarlo

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees